Cancer and Anorexia Nervosa in the Adolescence: A Family-Based Systemic Intervention

Objective. Anorexia nervosa is difficult to diagnose in cancer patients since weight loss, aversion for food, and eating disturbances are frequent in patients undergoing chemotherapy and radiotherapy. Nevertheless, efforts are mandatory to recognize and manage this condition which may occur also in cancer patients with a special regard to adolescents. Methods. Through the clinical history of Anna, a 15-year-old adolescent with advanced cancer, we describe the effectiveness of a family-based systemic intervention to manage anorexia nervosa occurring in concomitance to osteosarcoma. Results. Through a two-year psychotherapy period involving different techniques applied to the whole family such as family genogram, family collage, and sculpture of family time, Anna was relieved from her condition. Conclusions. Upon early diagnosis and appropriate treatment, anorexia nervosa can be effectively approached in adolescent cancer patients. The presence of a life-threatening medical condition such as cancer may provide motivation for a patient to control disordered eating behavior in the context of an appropriate family-based systemic intervention. The general frame of anorexia occurring in cancer-bearing adolescents is reviewed and discussed

Placing land cover preferences by users on the map: Bridging the gaps of landscape preference surveys and spatial pattern analysis in order to inform planning and policy

Landscapes provide several public goods, which, because they offer social, environmental and economic benefits, have become the focus of policy interest. Land cover patterns, being dynamic landscape components, are essential in delivering public goods. Public goods based on the social demand, such as recreation & landscape appreciation, have been progressively more acknowledged in environmental management as amenity demands steadily increase throughout Europe. As a result, there is a huge body of literature reporting landscape preferences both by the general public and of specific user groups in relation to multiple aspects of European landscapes. However, this empirical work has been revealing enormous challenges to be integrated into landscape planning and policy. This work offers two innovative outputs. One is to progress on gathering user group´s preferred land cover patterns, using in an innovative way, a non spatial model that is meaningful for respondents. The other is to map the preferences by different users into land cover pattern maps in one Alentejo municipality in order to assess the extent to which a certain landscape is likely to meet a specific social demand. Finally, the challenges for integrating the findings of this study into landscape planning and policy are discussed. The other is to relate the preferences expressed by the different users, to the Land Cover Patterns in one Alentejo municipality, to assess the extent to which a certain spatialized landscape has likelihood to meet a specific social demand

400G Frequency-Hybrid Superchannel for the 62.5 GHz Slot

We experimentally demonstrate a PM-16QAM/64QAM triple-carrier 400G superchannel compatible with the 62.5 GHz grid. The optimum power ratio between carriers is analytically determined using the EGN model, enabling a maximum reach of 1700 km

Cl-IB-MECA Inhibits Human Thyroid Cancer Cell Proliferation Independently of A3 Adenosine Receptor Activation

A3 adenosine receptor (A3AR) agonists have been reported to modulate cellular proliferation. This work was aimed to investigate the expression and the possible implication of A3AR in the human thyroid carcinomas. Normal thyroid tissue samples did not express A3 adenosine receptor, while primary thyroid cancer tissues expressed high level of A3AR, as determined by immunohistochemistry analysis. In human papillary thyroid carcinoma cell line, NPA, at concentrations > or =10 microM, the A3AR-selective agonist 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide (Cl-IB-MECA) produced inhibition of cell growth, by blocking the G(1) cell cycle phase in a concentration- and time-dependent manner. This effect was well correlated with a reduction of protein expression of cyclins D1 and E2 after 24 hours of Cl-IB-MECA treatment. Moreover Cl-IB-MECA induced dephosphorylation of ERK1/2 in a time- and concentration-dependent manner, which in turn inhibits cell proliferation. The effect of Cl-IB-MECA was not prevented by A3AR antagonists, MRS1191 or MRS1523 or FA385. Furthermore, neither nucleoside transporter inhibitors, Dypiridamole and NBTI, nor the A1, A2A and A2B receptors antagonists were able to block the response to Cl-IB-MECA. Although Cl-IB-MECA has been shown to influence cell death and survival in other systems through an A3AR-mediated mechanism, in NPA cells the growth inhibition induced by micromolar concentrations of Cl-IB-MECA is not related to A3AR activation and hence that its effects on human papillary carcinoma cell line seem to be independent of the presence of this receptor subtype

Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS

N

AIM2 Inflammasome Activation Leads to IL-1α and TGF-β Release From Exacerbated Chronic Obstructive Pulmonary Disease-Derived Peripheral Blood Mononuclear Cells

Chronic obstructive pulmonary disease (COPD) is now the fourth-leading cause of death worldwide and its prevalence is increasing. The progressive decline of lung function and airway remodelling are a consequence of chronic inflammatory responses. It was recently postulated the involvement of the inflammasome in COPD, although the underlying mechanism/s still need to be elucidated. Therefore, we isolated peripheral blood mononuclear cells (PBMCs) from exacerbated/unstable COPD patients. The stimulation of PBMCs with an AIM2 inflammasome activator, Poly dA:dT, led to IL-1α, but not IL-1β, release. The release of this cytokine was caspase-1- and caspase-4-dependent and correlated to higher levels of 8-OH-dG in COPD compared to non-smoker and smoker-derived PBMCs. Interestingly, AIM2-depedent IL-1α release was responsible for higher TGF-β levels, crucial mediator during pro-fibrotic processes associated to COPD progression. In conclusion, our data highlight the involvement of AIM2/caspase-1/caspase-4 in IL-1α-induced TGF-β release in unstable COPD-derived PBMCs, opening new therapeutic perspectives for unstable COPD patients

Precision measurement of the neutrino velocity with the ICARUS detector in the CNGS beam

During May 2012, the CERN-CNGS neutrino beam has been operated for two weeks for a total of 1.8 10^17 pot in bunched mode, with a 3 ns narrow width proton beam bunches, separated by 100 ns. This tightly bunched beam structure allows a very accurate time of flight measurement of neutrinos from CERN to LNGS on an event-by-event basis. Both the ICARUS-T600 PMT-DAQ and the CERN-LNGS timing synchronization have been substantially improved for this campaign, taking ad-vantage of additional independent GPS receivers, both at CERN and LNGS as well as of the deployment of the "White Rabbit" protocol both at CERN and LNGS. The ICARUS-T600 detector has collected 25 beam-associated events; the corresponding time of flight has been accurately evaluated, using all different time synchronization paths. The measured neutrino time of flight is compatible with the arrival of all events with speed equivalent to the one of light: the difference between the expected value based on the speed of light and the measured value is tof_c - tof_nu = (0.10 \pm 0.67stat. \pm 2.39syst.) ns. This result is in agreement with the value previously reported by the ICARUS collaboration, tof_c - tof_nu = (0.3 \pm 4.9stat. \pm 9.0syst.) ns, but with improved statistical and systematic errors.Comment: 21 pages, 13 figures, 1 tabl

Salerno Quadrante. N.1-3 (1955)

1 (giugno 1955): Guglielmo Longo, Ospedali, esigenza prima del Mezzo giorno, P. 3 ; Giuseppe Lanocita, Attualità della questione demaniale e suoi aspetti nel comune di Eboli, P. 9 ; Bilancio di un disastro: L'alluvione in cifre, P. 11 ; Alessandro Pinto, Canti popolari cilentani, P. 17 ; Giovanni Capasso, Poesie inedite, P. 18 ; Francesco Franco. S. Pietro al Tanagro, il paese dalle tovaglie di terra, P. 19 ; Antonio De Angelis, Scafati, cittadina di provincia, P. 23 ; Enzo Barba, Matteo Luciani, P. 25 ; Augusto Visconti, Curiosità e irrequietezza in tre giovani pittori salernitani: D'Agosto, Gentile, Della Monica, P. 28 ; II Centro di cultura Citta di Salerno, P. 29 ; Recensioni, P. 32- 40 ; La resistenza salernitana (fuori testo).2-3 (dicembre 1955): Ugo Renna, Viaggio nel Cilento, P. 3 ; Francesco Franco, La crisi tessile e Ie M.C.M. Fratte-Pellezzano, P. 14 ; Giuseppe Tortorella, II problema del Porto (intervista), P. 23 ; Guglielmo Longo, Difendiamo l'industria salernitana, P. 27 ; Enzo Barba, Errico de Marinis e il "socialismo demariniano, P. 33 ; Giuseppe Lanocita, Attualità della questione demaniale e suoi aspetti nel comune di Eboli, P. 43 ; Giuseppe A. Leone, Pietà per Crocco il brigante (poesia), p. 52 ; Gianni Nunziante, Titoli di proprietà immobiliare al portatore nella pratica medievale salernitana, P. 53 ; Mario Carotenuto, Olga Napoli nella pittura contemporanea (fuori testo)

Measurement of CNGS muon neutrino speed with Borexino

We have measured the speed of muon neutrinos with the Borexino detector using short-bunch CNGS beams. The final result for the difference in time-of-flight between a =17 GeV muon neutrino and a particle moving at the speed of light in vacuum is {\delta}t = 0.8 \pm 0.7stat \pm 2.9sys ns, well consistent with zero.Comment: 6 pages, 5 figure

Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study

Purpose: We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy. Methods: We randomly assigned treatment-naïve, advanced-stage, high-tumor burden follicular lymphoma patients to receive standard RM or a response-adapted postinduction approach on the basis of metabolic response and molecular assessment of minimal residual disease (MRD). The experimental arm used three types of postinduction therapies: for complete metabolic response (CMR) and MRD-negative patients, observation; for CMR and MRD-positive (end of induction or follow-up) patients, four doses of rituximab (one per week, maximum three courses) until MRD-negative; and for non-CMR patients, one dose of ibritumomab tiuxetan followed by standard RM. The study was designed as noninferiority trial with progression-free survival (PFS) as the primary end point. Results: Overall, 807 patients were randomly assigned. After a median follow-up of 53 months (range 1-92 months), patients in the standard arm had a significantly better PFS than those in the experimental arm (3-year PFS 86% v 72%; P < .001). The better PFS of the standard vs experimental arm was confirmed in all the study subgroups except non-CMR patients (n = 65; P = .274). The 3-year overall survival was 98% (95% CI, 96 to 99) and 97% (95% CI, 95 to 99) in the reference and experimental arms, respectively (P = .238). Conclusion: A metabolic and molecular response-adapted therapy as assessed in the FOLL12 study was associated with significantly inferior PFS compared with 2-year RM. The better efficacy of standard RM was confirmed in the subgroup analysis and particularly for patients achieving both CMR and MRD-negative